A 24-year-old man with a 3-year history of ulcerative colitis presents with 12 episodes of bloody diarrhoea daily, fever 38.6°C, tachycardia 118 bpm, hemoglobin 8.4 g/dL, ESR 78, and CRP 124 mg/L. Flexible sigmoidoscopy shows continuous confluent erythema, friability, deep ulcerations, and spontaneous bleeding from rectum to descending colon, confirming acute severe ulcerative colitis (ASUC) by Truelove & Witts criteria. The management pathway marked **A** in the diagram outlines the standard approach to this patient. Which of the following is NOT part of the initial management strategy outlined in pathway **A** for acute severe ulcerative colitis?
A. Oral mesalamine 4.8 g/day combined with IV corticosteroids as first-line therapy
B. Venous thromboembolism prophylaxis with low molecular weight heparin despite rectal bleeding
C. Daily clinical assessment using Oxford/Travis criteria at day 3 to guide rescue therapy decisions
D. Admission to a unit with colorectal surgical cover and IV methylprednisolone 60 mg/day
Explanation
Why oral mesalamine combined with IV corticosteroids is NOT part of initial ASUC management
In acute severe ulcerative colitis, oral mesalamine and oral corticosteroids have NO ROLE in first-line therapy. The ECCO Guidelines 2022 and BSG Guidelines 2019 mandate IV corticosteroids (methylprednisolone 60 mg/day or hydrocortisone 100 mg QDS) as monotherapy. Oral aminosalicylates are restricted to mild-to-moderate disease only and are ineffective in ASUC. Adding oral mesalamine to IV steroids does not improve outcomes and delays recognition of steroid refractoriness, potentially increasing the risk of toxic megacolon and the need for emergency colectomy.
Why each distractor is wrong
Admission with IV methylprednisolone 60 mg/day: This is the cornerstone of pathway A. Admission to a unit with colorectal surgical cover ensures multidisciplinary team involvement (gastroenterology, surgery, nutrition, stoma nurse) from day 1, and IV methylprednisolone is the first-line agent for ASUC.
VTE prophylaxis with LMWH despite rectal bleeding: Pathway A explicitly includes VTE prophylaxis because ulcerative colitis is a hypercoagulable state with 3-fold higher thromboembolism risk. LMWH is given even in the presence of rectal bleeding, as the thrombotic risk outweighs bleeding risk in ASUC.
Daily assessment and Oxford/Travis criteria at day 3: This is a critical component of pathway A. The Oxford/Travis criteria (stool frequency >8/day OR 3–8 stools plus CRP >45) predict ~85% colectomy risk without rescue therapy and guide the decision to escalate to infliximab or ciclosporin at day 3–5.
High-YieldNEET PG
In ASUC, use IV steroids ALONE as first-line; oral mesalamine is for mild-moderate disease only and has no place in acute severe flares.
ECCO Guidelines on UC 2022; BSG Guidelines IBD in Adults 2019; Truelove & Witts BMJ 1955; CONSTRUCT trial Lancet 2016
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
